Prelude Therapeutics clears FDA to start Phase 1 trial
The company received FDA clearance to proceed with a Phase 1 study of oral KAT6A degrader PRT13722. It expects patient enrollment in 4Q 2026.
Prelude Therapeutics said the FDA cleared it to begin a Phase 1 study of oral KAT6A degrader PRT13722. The company expects patient enrollment in 4Q 2026. Original SEC filing: Prelude Therapeutics Inc [ PRLD ] - 8-K - Sep. 10, 2026.